Leerink Partnrs Issues Negative Outlook for Revvity Earnings

Key Points

• Leering Partners has revised Revvity's Q4 2025 earnings per share (EPS) estimate down to $1.54, slightly below the previous estimate of $1.56.
• Revvity reported a Q2 earnings of $1.18 EPS, exceeding analysts' consensus of $1.14, and generated revenue of $720.28 million, representing a 4.1% year-over-year increase.
• The company has announced a quarterly dividend of $0.07 per share, reflecting an annualized dividend of $0.28 and a dividend yield of 0.3%.

Revvity Inc. (NYSE:RVTY - Free Report) - Equities research analysts at Leerink Partnrs cut their Q4 2025 earnings per share (EPS) estimates for Revvity in a research report issued to clients and investors on Sunday, September 14th. Leerink Partnrs analyst P. Souda now forecasts that the company will earn $1.54 per share for the quarter, down from their prior estimate of $1.56. The consensus estimate for Revvity's current full-year earnings is $4.94 per share. Leerink Partnrs also issued estimates for Revvity's Q1 2026 earnings at $1.14 EPS and Q3 2026 earnings at $1.35 EPS.

Revvity (NYSE:RVTY - Get Free Report) last announced its quarterly earnings results on Monday, July 28th. The company reported $1.18 EPS for the quarter, topping analysts' consensus estimates of $1.14 by $0.04. The company had revenue of $720.28 million during the quarter, compared to analyst estimates of $711.26 million. Revvity had a return on equity of 7.66% and a net margin of 10.19%.The firm's revenue was up 4.1% on a year-over-year basis. During the same quarter last year, the firm posted $1.22 earnings per share. Revvity has set its FY 2025 guidance at 4.850-4.950 EPS.

A number of other research analysts have also recently commented on the company. Stifel Nicolaus lowered their price target on Revvity from $120.00 to $110.00 and set a "hold" rating on the stock in a report on Tuesday, July 29th. Bank of America dropped their price target on Revvity from $116.00 to $110.00 and set a "buy" rating on the stock in a research report on Thursday, June 26th. Wall Street Zen cut Revvity from a "buy" rating to a "hold" rating in a research note on Sunday, August 3rd. Evercore ISI dropped their target price on Revvity from $116.00 to $115.00 and set an "outperform" rating on the stock in a report on Tuesday, July 8th. Finally, Raymond James Financial reaffirmed an "outperform" rating and issued a $115.00 price target (down from $120.00) on shares of Revvity in a research note on Tuesday, July 29th. Ten equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat.com, Revvity has a consensus rating of "Moderate Buy" and a consensus target price of $120.07.

Revvity Stock Performance

NYSE RVTY traded down $1.08 during trading hours on Wednesday, hitting $86.68. The company's stock had a trading volume of 3,530,393 shares, compared to its average volume of 1,176,729. Revvity has a 12 month low of $81.36 and a 12 month high of $129.50. The company's 50 day simple moving average is $90.03 and its two-hundred day simple moving average is $95.19. The company has a market cap of $10.06 billion, a P/E ratio of 36.73, a price-to-earnings-growth ratio of 2.33 and a beta of 0.94. The company has a debt-to-equity ratio of 0.43, a current ratio of 3.33 and a quick ratio of 2.75.

Institutional Investors Weigh In On Revvity

A number of hedge funds have recently bought and sold shares of the company. CYBER HORNET ETFs LLC acquired a new position in Revvity in the second quarter worth about $32,000. MUFG Securities EMEA plc bought a new stake in shares of Revvity during the second quarter valued at approximately $34,000. UMB Bank n.a. grew its stake in shares of Revvity by 138.8% during the second quarter. UMB Bank n.a. now owns 406 shares of the company's stock valued at $39,000 after purchasing an additional 236 shares during the last quarter. CVA Family Office LLC grew its stake in shares of Revvity by 79.0% during the second quarter. CVA Family Office LLC now owns 410 shares of the company's stock valued at $40,000 after purchasing an additional 181 shares during the last quarter. Finally, Vermillion Wealth Management Inc. bought a new stake in shares of Revvity during the fourth quarter valued at approximately $41,000. 86.65% of the stock is currently owned by institutional investors.

Revvity Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, November 7th. Shareholders of record on Friday, October 17th will be paid a dividend of $0.07 per share. This represents a $0.28 annualized dividend and a yield of 0.3%. The ex-dividend date of this dividend is Friday, October 17th. Revvity's payout ratio is 11.86%.

Revvity Company Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.